DaVita Inc(DVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 15.49 | EPS (ttm) | 11.86 | Insider Own | 2.08% | Shs Outstand | 63.8M | Perf Week | -1.96% |
| Market Cap | 11.72B | Forward P/E | 10.83 | EPS next Y | 14.42% | Insider Trans | -54.31% | Shs Float | 62.5M | Perf Month | 5.14% |
| Enterprise Value | 26.20B | PEG | 0.49 | EPS next Q | 3.57 | Inst Own | 93.41% | Short Float | 8.24% | Perf Quarter | -22.29% |
| Income | 0.82B | P/S | 0.84 | EPS this Y | 37.52% | Inst Trans | -3.46% | Short Ratio | 6.59 | Perf Half Y | 20.94% |
| Sales | 14.01B | P/B | - | EPS next 5Y | 21.92% | ROA | 4.67% | Short Interest | 5.15M | Perf YTD | 61.64% |
| Book/sh | -13.03 | P/C | 15.18 | EPS past 3/5Y | 18.56% 8.29% | ROE | - | 52W High | -25.8% ($247.49) | Perf Year | 43.45% |
| Cash/sh | 12.1 | P/FCF | 7.28 | Sales past 3/5Y | 5.53% 3.39% | ROIC | 6.81% | 52W Low | 81.82% ($101.00) | Perf 3Y | 132.84% |
| Dividend Est. | - | EV/EBITDA | 9.35 | EPS Y/Y TTM | 16.3% | Gross Margin | 27.29% | Volatility(W/M) | 5.03% 2.9% | Perf 5Y | 58.84% |
| Dividend TTM | - | EV/Sales | 1.87 | Sales Y/Y TTM | 6.45% | Oper. Margin | 14.93% | ATR (14) | 5.9 | Perf 10Y | 201.25% |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | EPS Q/Q | 55.84% | Profit Margin | 5.87% | RSI (14) | 51.8 | Recom | 2.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.47 | Sales Q/Q | 5.17% | SMA20 | 1.87% ($180.27) | Beta | 0.88 | Target Price | $229 |
| Payout | - | Debt/Eq | - | Earnings | 2026/10/29 | SMA50 | 1.72% ($180.53) | Rel Volume | 0.79 | Prev Close | $186.1 |
| Employees | 78000 | LT Debt/Eq | - | EPS/Sales Surpr. | 3.55% 1.65% | SMA200 | 4.89% ($175.08) | Avg Volume(3M) | 0.78M | Price | $183.64 |
| IPO | 1995/10/31 | Option/Short | Yes/Yes | Trades | 10281 | Volume | 618,100 | Change | -1.32% |
A leading U.S. provider of dialysis services, specializing in kidney care. The company operates a nationwide network of hemodialysis centers for patients with chronic kidney failure and offers related treatments and medical services, making it one of America's premier dialysis service companies.
Over the past 1 year, roughly in the middle
26% below its 1-year high.
Traded less than usual. That is 79% of its average volume.
Next earnings report: October 29
3 days to go.
DVA earns at a steady pace
Of every $100 in sales, $14.93 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +37.5% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $935. Peers typically go for $1,276. It is about in line with its own 5-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +58.8%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 93.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 48 in the industry
Based on market cap of $12B.
FAQ
What kind of company is DVA?
DVA belongs to the Healthcare sector and operates in the Medical Care Facilities industry.
What is the market cap of DVA?
The market cap of DVA is approximately $11.7B, ranking 828 within its sector.
What is the P/E ratio of DVA?
DVA has a P/E ratio of approximately 15.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for DVA?
DVA has recorded a 52-week high of $247.49 and a low of $101.00.
